BCR and B-cell chronic lymphocytic leukemia: In this context, the up-regulation of miR-132 upon BCR triggering and its specific abrogation upon exposure to the SYK inhibitor R406, as reported here, opens the possibility that in some instances, e.g. in M CLL, the down-regulation of the miR-132/SIRT1/TP53 axis by BCR inhibitors may paradoxically attenuate the clinical effects of BCR inhibitors in CLL.